Biomarker Window of Opportunity Study to Evaluate the Impact of Ribociclib on Head and Neck Squamous Cell Cancer
Phase of Trial: Phase 0
Latest Information Update: 25 May 2018
At a glance
- Drugs Ribociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 14 May 2018 Status changed from not yet recruiting to recruiting.
- 06 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.